POMDOCTOR LIMITED American Depositary Shares (POM) - Net Assets
Based on the latest financial reports, POMDOCTOR LIMITED American Depositary Shares (POM) has net assets worth $-481.30 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($107.56 Million) and total liabilities ($588.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See debt-free asset ratio of POMDOCTOR LIMITED American Depositary Sh to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-481.30 Million |
| % of Total Assets | -447.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -101.86% |
| Growth Volatility | 171.14 |
POMDOCTOR LIMITED American Depositary Shares - Net Assets Trend (2003–2025)
This chart illustrates how POMDOCTOR LIMITED American Depositary Shares's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see POMDOCTOR LIMITED American Depositary Sh market cap and net worth.
Annual Net Assets for POMDOCTOR LIMITED American Depositary Shares (2003–2025)
The table below shows the annual net assets of POMDOCTOR LIMITED American Depositary Shares from 2003 to 2025. Also explore POM net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-481.30 Million | +77.02% |
| 2024-12-31 | $-2.09 Billion | -6.80% |
| 2023-12-31 | $-1.96 Billion | -3.34% |
| 2022-12-31 | $-1.90 Billion | -6.78% |
| 2021-12-31 | $-1.78 Billion | -474.59% |
| 2020-12-31 | $-309.35 Million | -109.46% |
| 2019-12-31 | $3.27 Billion | -89.37% |
| 2018-12-31 | $30.76 Billion | +3.04% |
| 2017-12-31 | $29.86 Billion | +15.56% |
| 2016-12-31 | $25.84 Billion | +485.47% |
| 2015-12-31 | $4.41 Billion | +2.11% |
| 2014-12-31 | $4.32 Billion | +0.16% |
| 2013-12-31 | $4.32 Billion | -2.95% |
| 2012-12-31 | $4.45 Billion | +2.54% |
| 2011-12-31 | $4.34 Billion | +516.79% |
| 2010-12-31 | $703.00 Million | -93.51% |
| 2009-12-31 | $10.83 Billion | -2.39% |
| 2008-12-31 | $11.10 Billion | +6.94% |
| 2007-12-31 | $10.38 Billion | +5.07% |
| 2006-12-31 | $9.88 Billion | +7.61% |
| 2005-12-31 | $9.18 Billion | +10.89% |
| 2004-12-31 | $8.28 Billion | +2.67% |
| 2003-12-31 | $8.06 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to POMDOCTOR LIMITED American Depositary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 247599859400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.41K | % |
| Other Comprehensive Income | $-1.75 Million | % |
| Other Components | $2.02 Billion | % |
| Total Equity | $-453.97 Million | 100.00% |
POMDOCTOR LIMITED American Depositary Shares Competitors by Market Cap
The table below lists competitors of POMDOCTOR LIMITED American Depositary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GoHealth, Inc.
NASDAQ:GOCOQ
|
$5.62 Million |
|
Betacom S.A.
WAR:BCM
|
$5.63 Million |
|
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
|
$5.63 Million |
|
Ansal Properties & Infrastructure Limited
NSE:ANSALAPI
|
$5.63 Million |
|
Enquest Plc
LSE:ENQ
|
$5.62 Million |
|
Dlaboratory Sweden AB
ST:DLAB
|
$5.62 Million |
|
Boqii Holding Limited
NYSE:BQ
|
$5.61 Million |
|
Clearmind Medicine Inc. Common Shares
NASDAQ:CMND
|
$5.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in POMDOCTOR LIMITED American Depositary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,263,421,920 to -453,971,266, a change of 1,809,450,654.
- Net loss of 212,579,117 reduced equity.
- New share issuances of 163,932,614 increased equity.
- Other comprehensive income decreased equity by 1,747,229.
- Other factors increased equity by 1,859,844,386.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-212.58 Million | -46.83% |
| Share Issuances | $163.93 Million | +36.11% |
| Other Comprehensive Income | $-1.75 Million | -0.38% |
| Other Changes | $1.86 Billion | +409.68% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares POMDOCTOR LIMITED American Depositary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $6.84 | $0.83 | x |
| 2004-12-31 | $47.16 | $0.83 | x |
| 2005-12-31 | $48.49 | $0.83 | x |
| 2006-12-31 | $51.98 | $0.83 | x |
| 2007-12-31 | $53.49 | $0.83 | x |
| 2008-12-31 | $54.40 | $0.83 | x |
| 2009-12-31 | $47.93 | $0.83 | x |
| 2010-12-31 | $3.11 | $0.83 | x |
| 2011-12-31 | $19.19 | $0.83 | x |
| 2012-12-31 | $19.33 | $0.83 | x |
| 2013-12-31 | $17.54 | $0.83 | x |
| 2014-12-31 | $17.15 | $0.83 | x |
| 2015-12-31 | $17.37 | $0.83 | x |
| 2016-12-31 | $27.87 | $0.83 | x |
| 2017-12-31 | $31.46 | $0.83 | x |
| 2018-12-31 | $31.75 | $0.83 | x |
| 2019-12-31 | $3.36 | $0.83 | x |
| 2020-12-31 | $-0.32 | $0.83 | x |
| 2021-12-31 | $-281.02 | $0.83 | x |
| 2022-12-31 | $-300.09 | $0.83 | x |
| 2023-12-31 | $-322.18 | $0.83 | x |
| 2024-12-31 | $-343.97 | $0.83 | x |
| 2025-12-31 | $-7.82 | $0.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently POMDOCTOR LIMITED American Depositary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -53.16%
- • Asset Turnover: 3.72x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (6.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 0.66% | 4.23% | 0.09x | 1.67x | $-753.20 Million |
| 2004 | 3.12% | 3.57% | 0.54x | 1.61x | $-569.70 Million |
| 2005 | 4.04% | 4.60% | 0.58x | 1.53x | $-546.80 Million |
| 2006 | 2.51% | 2.97% | 0.59x | 1.44x | $-739.60 Million |
| 2007 | 3.22% | 3.57% | 0.62x | 1.46x | $-703.70 Million |
| 2008 | 2.70% | 2.80% | 0.65x | 1.48x | $-809.70 Million |
| 2009 | 2.17% | 2.54% | 0.59x | 1.46x | $-848.20 Million |
| 2010 | 7.54% | 0.75% | 2.45x | 4.09x | $-17.30 Million |
| 2011 | 5.93% | 4.34% | 0.40x | 3.44x | $-176.60 Million |
| 2012 | 6.41% | 5.61% | 0.32x | 3.55x | $-159.60 Million |
| 2013 | -4.91% | -4.54% | 0.31x | 3.44x | $-643.50 Million |
| 2014 | 5.60% | 4.96% | 0.31x | 3.62x | $-190.20 Million |
| 2015 | 7.41% | 6.51% | 0.31x | 3.70x | $-114.30 Million |
| 2016 | 4.39% | 3.62% | 0.27x | 4.45x | $-1.45 Billion |
| 2017 | 9.02% | 8.03% | 0.29x | 3.91x | $-291.70 Million |
| 2018 | 1.29% | 1.11% | 0.30x | 3.89x | $-2.68 Billion |
| 2019 | 92.63% | 8.79% | 5.11x | 2.06x | $2.70 Billion |
| 2020 | 0.00% | -181.61% | 1.82x | 0.00x | $-225.50 Million |
| 2021 | 0.00% | -87.47% | 11.15x | 0.00x | $-3.49 Million |
| 2022 | 0.00% | -51.18% | 5.04x | 0.00x | $71.96 Million |
| 2023 | 0.00% | -47.69% | 4.60x | 0.00x | $66.61 Million |
| 2024 | 0.00% | -41.85% | 7.41x | 0.00x | $82.98 Million |
| 2025 | 0.00% | -53.16% | 3.72x | 0.00x | $-167.18 Million |
Industry Comparison
This section compares POMDOCTOR LIMITED American Depositary Shares's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $3,020,669,527
- Average return on equity (ROE) among peers: -407.36%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| POMDOCTOR LIMITED American Depositary Shares (POM) | $-481.30 Million | 0.66% | N/A | $5.62 Million |
| Bimi International Medical Inc (BIMI) | $-178.41K | 0.00% | 0.00x | $1.40K |
| High Tide Inc (HITI) | $133.67 Million | -29.41% | 0.75x | $204.80 Million |
| Trxade Group Inc (MEDS) | $-1.15 Million | 0.00% | 0.00x | $1.60 Million |
| PetMed Express Inc (PETS) | $115.73 Million | 32.22% | 0.17x | $38.68 Million |
| Ridgetech, Inc. (RDGT) | $52.35 Million | 15.55% | 0.43x | $3.30 Million |
| Scienture Holdings, Inc. (SCNX) | $542.35K | -3290.03% | 22.11x | $15.16 Million |
| SunLink Health Systems Inc (SSY) | $42.39 Million | 2.15% | 1.53x | $7.85 Million |
| Walgreens Boots Alliance Inc (WBA) | $23.82 Billion | 10.67% | 2.41x | $10.37 Billion |
About POMDOCTOR LIMITED American Depositary Shares
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company in involv… Read more